University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Matthew Cooperberg, M.D.

Genitourinary cancer specialist

Dr. Matthew Cooperberg is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the diagnosis and management of genitourinary cancer, and using minimally invasive techniques to treat benign and malignant diseases. Cooperberg, who is interested in new technologies, performs robotic, laparoscopic, endoscopic and percutaneous surgeries. He developed a new prostate cancer risk assessment tool called the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score.

Cooperberg earned a medical degree and master's of public health at Yale University. He then completed training in general surgery and urology at UCSF, followed by a urologic oncology fellowship under the guidance of Dr. Peter Carroll. Cooperberg is a candidate member of the American Urological Association (AUA), Western Section of the AUA and the American College of Surgeons. He has written over 50 peer-reviewed scientific articles, nine chapters and has lectured nationally and internationally about malignant and benign urologic disease, with a particular focus on prostate cancer.

Clinics

Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Matthew Cooperberg

Additional Languages

Spanish

Education

Yale University School of Medicine 2000

Residencies

UCSF Medical Center, Urology 2008

Selected Research and Publications

  1. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7; 314(1):80-2.
  2. Cooperberg MR. Editorial Comment. Urology. 2015 Jun; 85(6):1223.
  3. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6.
  4. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62.
  5. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May; 51(7):817-24.
  6. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6.
  7. Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):149-54.
  8. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. Eur Urol. 2015 Sep; 68(3):480-6.
  9. Basto M, Cooperberg MR, Murphy DG. Proton therapy Websites: information anarchy creates confusion. BJU Int. 2015 Feb; 115(2):183-5.
  10. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
  11. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104.
  12. Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol. 2015 Jan; 25(1):65-70.
  13. Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015 Jan 20; 33(3):238-40.
  14. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 1; 121(9):1414-21.
  15. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. J Urol. 2015 Apr; 193(4):1232-8.
  16. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
  17. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56.
  18. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  19. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific Variation in Outcomes for Men Treated With Primary Androgen Deprivation Therapy for Prostate Cancer. BJU Int. 2014 Sep 19.
  20. Cooperberg MR. Progress in Management of Low-risk Prostate Cancer: How Registries May Change the World. Eur Urol. 2015 Jan; 67(1):51-2.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.